Ceftazidime/Avibactam Monotherapy Versus Other Antibiotics: Where Do We Stand?

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• The rise of multidrug-resistant (MDR) pathogens, particularly those producing beta-lactamases like extended spectrum beta-lactamases (ESBLs), necessitates alternative treatments.
• Emergence of carbapenemase-producing pathogens presents a significant global health challenge, limiting treatment options.
• Carbapenems are often used as last-line antibiotics, but resistance is increasing.

Purpose of the Study:

• To review the efficacy and safety of ceftazidime/avibactam (CAZ/AVI) for treating multidrug-resistant Gram-negative infections.
• To evaluate CAZ/AVI's performance across various clinical settings and patient populations.
• To compare CAZ/AVI with existing treatments like carbapenems and polymyxins.

Main Methods:

• Systematic review of randomized controlled trials and cohort studies.
• Analysis of clinical outcomes and safety data for CAZ/AVI.
• Evaluation of CAZ/AVI's spectrum of activity against Ambler Class A, C, and D beta-lactamases.

Main Results:

• Avibactam inhibits a broad range of beta-lactamases, including ESBLs and carbapenemases (KPC, OXA-type).
• CAZ/AVI demonstrated non-inferiority to carbapenems and superiority over polymyxins in clinical outcomes and safety.
• Effective in diverse infections: complicated intra-abdominal, urinary tract, nosocomial pneumonia, skin/soft tissue, and bloodstream infections.

Conclusions:

• CAZ/AVI is a potent therapeutic option against resistant Gram-negative pathogens.
• Favorable efficacy and safety profile supports its use as a frontline treatment.
• Evidence supports CAZ/AVI use in high-risk groups, including immunocompromised and critically ill patients.